Exercise training after upper gastrointestinal cancer surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center randomized trial compares three post-surgical approaches for adults with upper gastrointestinal cancer: high-intensity interval training, low-intensity continuous training, and usual care. Participants begin 6±2 weeks after surgery and train under supervision three times per week for eight weeks, combining aerobic and resistance exercises. The study’s primary outcome is change in peak oxygen uptake (VO2 peak) measured by cardiopulmonary testing, with secondary outcomes including physical function, body composition, quality of life, self-reported outcomes, and biological markers such as inflammatory factors and gut microbiome. The goal is to understand how exercise intensity influences recovery and to explore underlying mechanisms of exercise adaptations in the early postoperative period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* Diagnosed with esophageal or gastric cancer
* Received curative surgery
* 6 ± 2 weeks after surgery
* Ability to provide written informed consent

Exclusion Criteria:

* Communication difficulties
* Poor general status
* Undergone combined laryngopharyngectomy
* Unsuitable for evaluation or exercise intervention
* Unsuitable for the study as determined by the primary physician

Where it's running

• Kansai Medical University
  Hirakata, Osaka, Japan Recruiting
• Kansai Medical University
  Hirakata, Osaka, Japan Not yet recruiting

Study contacts

• Principal investigator: Takuya Fukushima — Kansai Medical University
• Study coordinator: Takuya Fukushima
• Email: fukushima.tky@kmu.ac.jp
• Phone: +81-72-856-2115

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High-flow nasal oxygen to prevent low oxygen during sedated endoscopy in people with high-risk sleep apnea

  This will test whether using high‑flow nasal oxygen instead of a regular nasal cannula prevents low oxygen levels during propofol‑sedated gastroscopy or colonoscopy in adults with high‑risk obstructive sleep apnea (STOP‑Bang ≥5).

  Recruiting at 3 sites Zhejiang University · Hangzhou, Zhejiang and 2 other locations · NCT07307560

• PF-08098488 in adults with advanced solid tumors

  This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.

  Recruiting at 4 sites Phase 1 Pfizer · Grand Rapids, Michigan and 3 other locations · NCT07903415

• Modular Robot-Assisted Esophagectomy vs. Conventional Minimally Invasive Esophagectomy for Esophageal Cancer

  This trial tests whether modular robotic-assisted esophagectomy using the Carina platform works better than conventional 3D thoracoscopic esophagectomy for people with resectable esophageal cancer.

  Recruiting Phase 3 Ruijin Hospital · Shanghai · NCT07888140

• MGC030 in adults with advanced solid tumors

  This trial tests MGC030 in adults with advanced urothelial, gastric/GEJ, esophageal, colorectal, gastric, pancreatic, or GEJ cancers to see if it is safe and whether it can shrink tumors or stop growth.

  Recruiting Phase 1 MacroGenics · Lake Success, New York · NCT07822399

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• TS-104: a first-in-human, dose-escalation study for advanced solid tumors

  This study tests TS-104, a peptide-drug conjugate, as a single therapy in adults with advanced solid tumors like NSCLC, HNSCC, esophageal, gastric, ovarian, or endometrial cancer to see if it is safe and tolerable and whether it shows any benefit.

  Recruiting at 3 sites Phase 1 TwoStep Therapeutics, Inc. · Maumee, Ohio and 2 other locations · NCT07814248

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.